Brief: Aurobindo Pharma Says First Us FDA Submission Planned In FY26
26/05/2025 15:31
May 26 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: AUROBINDO PHARMA - FIRST US FDA SUBMISSION PLANNED IN FY26 AUROBINDO PHARMA - 8 BIOSIMILAR CANDIDATES WITH TAM OF GT50 BILLION USD IN 2030 UNDER DEVELOPMENT Source text: [ID:] Further company coverage: ARBN.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11